Skip to main content
. 2022 Nov 22;29(12):9046–9065. doi: 10.3390/curroncol29120709
# Searches Results
1 small cell lung cancer.mp. 66,316
2 exp Small Cell Lung Carcinoma/ 3993
3 1 or 2 67,529
4 immunotherapy.mp. 105,565
5 Programmed Cell Death 1 Receptor/or PD1 inhibitor.mp. or PDL1 inhibitor.mp. 6485
6 CTLA-4 Inhibitor.mp. 91
7 pembrolizumab.mp. 3958
8 nivolumab.mp. or nivolumab/ 5008
9 ipilimumab.mp. or Ipilimumab/ 3565
10 avelumab.mp. 422
11 tremelimumab.mp. 283
12 atezolizumab.mp. 1067
13 durvalumab.mp. 503
14 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 114,500
15 Antineoplastic Agents/ 277,204
16 cisplatin.mp. or Cisplatin/ 75,659
17 carboplatin.mp. or Carboplatin/ 17,588
18 Paclitaxel.mp. or Paclitaxel/ 37,346
19 etoposide.mp. or Etoposide/ 25,396
20 chemotherapy.mp. 441,677
21 15 or 16 or 17 or 18 or 19 or 20 669,235
22 randomised controlled trial.pt. 507,927
23 controlled clinical trial.pt. 93,720
24 randomised.ab. 483,103
25 placebo.ab. 208,619
26 drug therapy.fs. 2,212,406
27 randomly.ab. 335,363
28 trial.ab. 509,238
29 groups.ab. 2,058,166
30 22 or 23 or 24 or 25 or 26 or 27 or 28 or 29 472,7391
31 animals/ 6,621,020
32 human/ 18,535,892
33 31 not (31 and 32) 4,675,617
34 30 not 33 4,101,212
35 3 and 14 and 21 and 34 1125
35 limit 34 to yr = “2010-Current” 1040